# A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

> **NCT03018405** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Celyad Oncology SA** · enrollment: 146 (estimated)

## Conditions studied

- Acute Myeloid Leukemia/Myelodysplastic Syndrome
- Multiple Myeloma (MM)

## Interventions

- **BIOLOGICAL:** NKR-2 cells

## Key facts

- **NCT ID:** NCT03018405
- **Lead sponsor:** Celyad Oncology SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2021-05
- **Final completion:** 2021-08
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03018405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03018405, "A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03018405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*